Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03857503
Other study ID # 180102
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 1, 2019
Est. completion date March 12, 2021

Study information

Verified date March 2021
Source Volcano Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Philips Angio-iFR medical software device is intended to provide information on the functional significance of a coronary artery lesion to provide guidance on diagnostic decisions similar to that obtained through invasive measures of iFR and FFR. The software application uses the vessel geometry obtained from a coronary angiographic image together with a lumped parameter physiological model to provide the associated iFR and FFR estimates.


Description:

This study is intended to demonstrate the diagnostic performance of the image-derived physiology model using the invasive physiological measures as the reference standard. Specific objectives include the following: i) Demonstrate the sensitivity and specificity of image-derived iFR and FFR results for identifying functionally significant lesions as determined by the corresponding invasive measures; ii) Demonstrate the diagnostic agreement of image-derived iFR and FFR estimates with the corresponding invasive measures; iii) Demonstrate the diagnostic performance of image derived physiology estimate (iFR/FFR) is superior to visual angiographic assessment for the identification of functionally significant stenoses as determined by the corresponding invasive physiology measures; iv) Demonstrate reproducibility of the image-derived estimate for a given operator and across multiple operators for a given lesion.


Recruitment information / eligibility

Status Completed
Enrollment 441
Est. completion date March 12, 2021
Est. primary completion date March 12, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. =18 years old 2. At least 1 de-novo lesion in 1 or more major epicardial vessels of 40-90% angiographic stenosis with a reference vessel size =2.5mm in the diseased segment by visual estimate 3. Able and willing to provide informed consent Exclusion Criteria: 1. Presenting with an acute coronary syndrome (ACS), or documented ACS within 4 weeks prior to the scheduled index procedure 2. Cardiogenic shock (sustained (>10 min) systolic blood pressure <90 mmHg in absence of inotropic support or the presence of an intra-aortic balloon pump) 3. Presence of cardiac arrhythmias (e.g., atrial fibrillation, AV-block) 4. Prior cardiac surgery or implant, including CABG, heart transplant, surgical heart valve replacement or repair, TAVI/TAVR, presence of an ICD or pacemaker 5. Target vessel supplied by a left main coronary artery demonstrating any disease present (isolated or non-isolated) 6. Target vessel supplied by right coronary artery demonstrating any ostial disease (located immediately at the origin of the coronary vessels from the aorta) 7. Target vessel with Chronic Total Occlusion (CTO) in the ipsilateral territory or target vessel with an untreated CTO in the contralateral territory. Note: if a CTO existing in the contralateral territory is successfully opened, the target vessel in the contralateral territory can be included following CTO treatment. 8. Target vessel with severe tortuosity (=1 bends of 90° or more, or =3 or more bends of 45°- 90° proximal to the diseased segment) 9. Target vessel with heavy calcification (multiple persisting opacifications of the coronary wall visible in more than one projection surrounding the complete lumen of the coronary artery at the site of the lesion.) 10. Target vessel with TIMI flow grade 1 or 0 11. Target vessel with severe diffuse disease (more than 75% of the length of the segment having a vessel diameter of 2mm, irrespective of the presence or absence of a lesion) 12. Target lesion is at a bifurcation/trifurcation 13. Target arteries supplying akinetic or severely hypokinetic territories if already known based on prior imaging 14. Target vessel is supplied by major collaterals 15. Target stenosis associated with myocardial bridge 16. Any vascular abnormality precluding optimal contrast opacification (e,g, thrombus, ulceration) 17. Severe aortic or mitral valve disease 18. Known ejection fraction =30% 19. Known severe renal insufficiency (eGFR<30ml/min/1.72m2) 20. Any fluoroscopic interference that renders the wire position unclear 21. Contraindication for adenosine or other hyperemic agent (e.g., caffeine ingestion =18 hours, COPD, hypotension, AV block) 22. Known pregnancy or planning to become pregnant 23. Participating in another interventional investigational study

Study Design


Intervention

Diagnostic Test:
iFR
Patients will undergo standard of care diagnostic coronary angiography using established invasive physiological criteria for iFR and FFR to aid in clinical decision making for coronary revascularization. Angiograms will be made in at least two projections, and the treating physician will record his/her estimation of stenosis severity. Resting iFR and Pd/Pa measures will then be made distal to the target lesion; adenosine will be administered, and the FFR measures will be made without moving the wire. An iFR pullback will then be made after hyperemia as abated. Patients will be treated or deferred from treatment based on physician decision aided by the iFR measures.

Locations

Country Name City State
Germany Unversitatklinikum, Freiburg Freiburg
Germany Gemeinschaftsklinikum, Koblenz Koblenz
Germany Universitatklinikum, Mannheim Mannheim
Germany Robert-Bosch Krankenhaus, Stuttgart Stuttgart
Ireland University Hospital Galway, CRFG Galway
Japan Gifu Heart Center Gifu
Japan Ehime Medical University Matsuyama
Japan Wakayama Medical University Wakayama
Netherlands AMC Amsterdam Amsterdam
Netherlands Amphia Ziekenhuis Breda Breda
Netherlands Medische Spectrum Twente Enschede
Netherlands Medisch Centrum Leeuwarden Leeuwarden
Netherlands Sint Antonius Ziekenhuis Nieuwegein
Netherlands Radboud UMC Nijmegen
Spain Hospital Universitario de Léon León
Spain Hospital Clinico San Carlos Madrid
United Kingdom Basildon Univeristy Hospital Basildon
United Kingdom Blackpool Victoria hospital Blackpool
United Kingdom Royal Bournemouth hospital Bournemouth
United Kingdom Imperial College of London- Hammersmith Hospital London
United Kingdom University of Southampton Southampton
United States Emory University Hospital Atlanta Georgia
United States South Side Hospital Bay Shore New York
United States University at Buffalo Buffalo New York
United States Baylor Scott & White Research Institute Dallas Texas
United States Midwest Cardiovascular Research Foundation Davenport Iowa
United States Ascension St. John Hospital Detroit Michigan
United States Duke University Hospital Durham North Carolina
United States NC Heart & Vascular Goldsboro North Carolina
United States Memorial Regional Hospital Hollywood Florida
United States Colorado Heart and Vascular/St Anthony's Lakewood Colorado
United States VA Medical Center Long Beach California
United States Catholic Medical Center Manchester New Hampshire
United States Centennial Heart Nashville Tennessee
United States Yale University Hospital New Haven Connecticut
United States Integris Heart Hospital Oklahoma City Oklahoma
United States Memorial Hospital- West Pembroke Pines Florida
United States St Francis Hospital Roslyn New York
United States Bryn Mawr Hospital Wynnewood Pennsylvania
United States Lankenau Medical Center Wynnewood Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Volcano Corporation

Countries where clinical trial is conducted

United States,  Germany,  Ireland,  Japan,  Netherlands,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic accuracy of the image-derived iFR Diagnostic accuracy of the image-derived iFR and FFR estimate for a given lesion compared to the corresponding invasive iFR and FFR values. 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A